NewAmsterdam Pharma (NAMS) Set to Post Earnings on Wednesday

NewAmsterdam Pharma (NASDAQ:NAMS) will likely be posting its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.4949) per share and revenue of $7.54 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 9:30 AM ET.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%. The business had revenue of $3.70 million during the quarter, compared to the consensus estimate of $2.83 million. On average, analysts expect NewAmsterdam Pharma to post ($1.82) EPS for the current fiscal year and ($1.62) EPS for the next fiscal year.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS opened at $19.56 on Tuesday. NewAmsterdam Pharma has a 1 year low of $19.13 and a 1 year high of $42.21. The company has a market cap of $2.34 billion, a PE ratio of -9.06 and a beta of 0.10. The stock’s 50-day moving average is $22.69 and its 200 day moving average is $29.77.

Insider Activity

In related news, Director John W. Smither sold 1,600 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $25.32, for a total transaction of $40,512.00. Following the transaction, the director owned 8,760 shares in the company, valued at $221,803.20. The trade was a 15.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael Davidson purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The stock was bought at an average cost of $22.65 per share, with a total value of $226,500.00. Following the completion of the purchase, the chief executive officer owned 792,923 shares of the company’s stock, valued at $17,959,705.95. This represents a 1.28% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have sold 176,846 shares of company stock valued at $4,661,919. Corporate insiders own 12.74% of the company’s stock.

Wall Street Analyst Weigh In

NAMS has been the topic of a number of recent analyst reports. BMO Capital Markets initiated coverage on NewAmsterdam Pharma in a research report on Monday, July 20th. They issued an “outperform” rating and a $58.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, October 15th. Jefferies Financial Group restated a “buy” rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a report on Monday, July 20th. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Sunday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $52.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $48.90.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma (NASDAQ: NAMS) is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases. The company’s primary investigational product is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and potentially address residual cardiovascular risk in patients who remain inadequately controlled on existing treatments.

NewAmsterdam is evaluating obicetrapib in late-stage clinical studies involving patients with dyslipidemia, including individuals with heterozygous familial hypercholesterolemia and patients who are unable to reach cholesterol goals with currently available therapies.